Ascendis Pharma (ASND) has released an update. Ascendis Pharma reported a revenue of €57.8 million in Q3 2024, driven by product launches and ...
Ascendis Pharma (ASND) is scheduled to announce Q3 earnings results on Thursday, November 14th, after market close. The ...
GlobalData on MSN9d
Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RANovo Nordisk and Ascendis Pharma have agreed to collaborate in developing metabolic and cardiovascular therapies, among them ...
The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...
Ascendis Pharma (ASND) has released an update. Ascendis Pharma has entered a collaboration with Novo Nordisk to license its ...
Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.
The Danish pharmaceutical giant is putting up $285 million to begin a strategic alliance granting the pharmaceutical giant access to Ascendis Pharma technology that could develop its drugs for ...
On Monday, Ascendis Pharma A/S (NASDAQ:ASND) granted Novo Nordisk A/S (NYSE:NVO) an exclusive worldwide license. The pact ...
Novo Nordisk acquires exclusive worldwide license to Ascendis Pharma’s TransCon technology for developing metabolic and ...
In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Ascendis Pharma (ASND – Research Report), with a price target of $167.00. The company’s shares closed last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback